Marshall Wace
TXG icon

Marshall Wace’s 10x Genomics TXG Stock Holding History

Marshall Wace’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-102,272
Closed -$2.17M – 3769
2026
Q1 		$2.17M Buy
102,272
+10,572
+12% +$211K ﹤0.01% 1736
2025
Q4 		$1.5M Buy
91,700
+40,701
+80% +$615K ﹤0.01% 1728
2025
Q3 		$596K Sell
50,999
-348,703
-87% -$4.55M ﹤0.01% 2163
2025
Q2 		$4.63M Sell
399,702
-17,749
-4% -$162K 0.01% 1175
2025
Q1 		$3.64M Buy
417,451
+370,590
+791% +$4.67M ﹤0.01% 1200
2024
Q4 		$673K Sell
46,861
-420,262
-90% -$6.63M ﹤0.01% 1917
2024
Q3 		$10.5M Buy
467,123
+431,722
+1,220% +$8.93M 0.01% 743
2024
Q2 		$689K Buy
+35,401
New +$927K ﹤0.01% 1835
2024
Q1 		– Sell
-7,516
Closed -$421K – 2808
2023
Q4 		$421K Buy
+7,516
New +$327K ﹤0.01% 1778
2023
Q3 		– Sell
-197,321
Closed -$11M – 2699
2023
Q2 		$11M Buy
+197,321
New +$10.7M 0.02% 689
2023
Q1 		– Sell
-19,268
Closed -$702K – 3114
2022
Q4 		$702K Buy
+19,268
New +$630K ﹤0.01% 2231
2022
Q1 		– Sell
-9,704
Closed -$1.45M – 4036
2021
Q4 		$1.45M Sell
9,704
-287,639
-97% -$44.1M ﹤0.01% 2261
2021
Q3 		$43.3M Buy
+297,343
New +$51M 0.18% 100
2021
Q1 		– Sell
-257,149
Closed -$36.4M – 2869
2020
Q4 		$36.4M Buy
257,149
+165,325
+180% +$24M 0.2% 107
2020
Q3 		$11.4M Buy
91,824
+72,924
+386% +$7.65M 0.07% 262
2020
Q2 		$1.69M Sell
18,900
-39,859
-68% -$3.1M 0.01% 847
2020
Q1 		$3.66M Buy
+58,759
New +$4.59M 0.04% 461

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's TXG Position: Q2 2026 in Review

Marshall Wace sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 102,272 shares — an estimated $2.17M sold.

Marshall Wace first reported a position in TXG in Q1 2020 and held it in 17 quarters. The position peaked at $43.3M in Q3 2021. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Marshall Wace reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 102,272 10x Genomics shares in Q2 2026, an estimated $2.17M.
  • Marshall Wace first reported a position in 10x Genomics in Q1 2020 and held it in 17 quarters.
  • Marshall Wace's 10x Genomics position peaked at $43.3M in Q3 2021.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.